Home Applications 218316 Application 218316
Type NDA
Sponsor NOVO Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 WEGOVY SEMAGLUTIDE TABLET;ORAL 1.5MG Yes Yes 002 WEGOVY SEMAGLUTIDE TABLET;ORAL 4MG Yes Yes 003 WEGOVY SEMAGLUTIDE TABLET;ORAL 9MG Yes Yes 004 WEGOVY SEMAGLUTIDE TABLET;ORAL 25MG Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 42 .
Orange Book products# Current product rows page 1 of 1 · 4 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N218316-001 WEGOVY SEMAGLUTIDE 1.5MG TABLET / ORAL RLD, RS 2025-12-22 N218316-002 WEGOVY SEMAGLUTIDE 4MG TABLET / ORAL RLD, RS 2025-12-22 N218316-003 WEGOVY SEMAGLUTIDE 9MG TABLET / ORAL RLD, RS 2025-12-22 N218316-004 WEGOVY SEMAGLUTIDE 25MG TABLET / ORAL RLD, RS 2025-12-22
Orange Book patents# Current patent rows page 1 of 1 · 34 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N218316-001 8536122 2026-03-20 Drug substance, Drug product 2026-02-04 N218316-001 8129343 2031-12-05 Drug substance, Drug product 2026-02-04 N218316-001 11382957 2031-12-16 Drug product 2026-01-16 N218316-001 11033499 2033-06-19 U-4496 Drug product 2026-05-07 N218316-001 10278923 2034-05-02 U-4389 2026-01-16 N218316-001 12239739 2034-05-02 U-4388 2026-01-16 N218316-001 11833248 2039-02-01 U-4387 Drug product 2026-01-16 N218316-001 12396953 2039-02-01 U-4387 Drug product 2026-01-16 N218316-002 8536122 2026-03-20 Drug substance, Drug product 2026-02-04 N218316-002 8129343 2031-12-05 Drug substance, Drug product 2026-02-04 N218316-002 11382957 2031-12-16 Drug product 2026-01-16 N218316-002 11033499 2033-06-19 U-4496 Drug product 2026-05-07 N218316-002 10278923 2034-05-02 U-4389 2026-01-16 N218316-002 12239739 2034-05-02 U-4388 2026-01-16 N218316-002 11833248 2039-02-01 U-4387 Drug product 2026-01-16 N218316-002 12396953 2039-02-01 U-4387 Drug product 2026-01-16 N218316-003 8536122 2026-03-20 Drug substance, Drug product 2026-02-04 N218316-003 8129343 2031-12-05 Drug substance, Drug product 2026-02-04 N218316-003 11382957 2031-12-16 Drug product 2026-01-16 N218316-003 9278123 2031-12-16 U-4389 Drug product 2026-02-05 N218316-003 11033499 2033-06-19 U-4496 Drug product 2026-05-07 N218316-003 10278923 2034-05-02 U-4389 2026-01-16 N218316-003 12239739 2034-05-02 U-4388 2026-01-16 N218316-003 11833248 2039-02-01 U-4387 Drug product 2026-01-16 N218316-003 12396953 2039-02-01 U-4387 Drug product 2026-01-16 N218316-004 8536122 2026-03-20 Drug substance, Drug product 2026-02-04 N218316-004 8129343 2031-12-05 Drug substance, Drug product 2026-02-04 N218316-004 11382957 2031-12-16 Drug product 2026-01-16 N218316-004 9278123 2031-12-16 U-4389 Drug product 2026-01-16 N218316-004 11033499 2033-06-19 U-4496 Drug product 2026-05-07 N218316-004 10278923 2034-05-02 U-4389 2026-01-16 N218316-004 12239739 2034-05-02 U-4388 2026-01-16 N218316-004 11833248 2039-02-01 U-4387 Drug product 2026-01-16 N218316-004 12396953 2039-02-01 U-4387 Drug product 2026-01-16
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 8 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-08-18 06:07:40 2026-07 N218316-001 WEGOVY 1.5MG TABLET / ORAL RLD, RS 2025-12-22 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-002 WEGOVY 4MG TABLET / ORAL RLD, RS 2025-12-22 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-003 WEGOVY 9MG TABLET / ORAL RLD, RS 2025-12-22 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-004 WEGOVY 25MG TABLET / ORAL RLD, RS 2025-12-22 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N218316-001 WEGOVY 1.5MG TABLET / ORAL RLD 2025-12-22 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218316-002 WEGOVY 4MG TABLET / ORAL RLD 2025-12-22 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218316-003 WEGOVY 9MG TABLET / ORAL RLD 2025-12-22 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218316-004 WEGOVY 25MG TABLET / ORAL RLD, RS 2025-12-22 011fe1cb6892…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218316-001 WEGOVY 1.5MG TABLET / ORAL RLD, RS 2025-12-22 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218316-002 WEGOVY 4MG TABLET / ORAL RLD, RS 2025-12-22 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218316-003 WEGOVY 9MG TABLET / ORAL RLD, RS 2025-12-22 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N218316-004 WEGOVY 25MG TABLET / ORAL RLD, RS 2025-12-22 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 3 · 98 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-08-18 06:07:40 2026-07 N218316-001 8536122 2026-03-20 Drug substance, Drug product 2026-02-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-001 8129343 2031-12-05 Drug substance, Drug product 2026-02-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-001 11382957 2031-12-16 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-001 11033499 2033-06-19 U-4496 Drug product 2026-05-07 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-001 10278923 2034-05-02 U-4389 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-001 12239739 2034-05-02 U-4388 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-001 11833248 2039-02-01 U-4387 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-001 12396953 2039-02-01 U-4387 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-002 8536122 2026-03-20 Drug substance, Drug product 2026-02-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-002 8129343 2031-12-05 Drug substance, Drug product 2026-02-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-002 11382957 2031-12-16 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-002 11033499 2033-06-19 U-4496 Drug product 2026-05-07 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-002 10278923 2034-05-02 U-4389 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-002 12239739 2034-05-02 U-4388 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-002 11833248 2039-02-01 U-4387 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-002 12396953 2039-02-01 U-4387 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-003 8536122 2026-03-20 Drug substance, Drug product 2026-02-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-003 8129343 2031-12-05 Drug substance, Drug product 2026-02-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-003 11382957 2031-12-16 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-003 9278123 2031-12-16 U-4389 Drug product 2026-02-05 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-003 11033499 2033-06-19 U-4496 Drug product 2026-05-07 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-003 10278923 2034-05-02 U-4389 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-003 12239739 2034-05-02 U-4388 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-003 11833248 2039-02-01 U-4387 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-003 12396953 2039-02-01 U-4387 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-004 8536122 2026-03-20 Drug substance, Drug product 2026-02-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-004 8129343 2031-12-05 Drug substance, Drug product 2026-02-04 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-004 11382957 2031-12-16 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-004 9278123 2031-12-16 U-4389 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-004 11033499 2033-06-19 U-4496 Drug product 2026-05-07 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-004 10278923 2034-05-02 U-4389 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-004 12239739 2034-05-02 U-4388 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-004 11833248 2039-02-01 U-4387 Drug product 2026-01-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N218316-004 12396953 2039-02-01 U-4387 Drug product 2026-01-16 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N218316-001 8536122 2026-03-20 Drug substance, Drug product 2026-02-04 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218316-001 8129343 2031-12-05 Drug substance, Drug product 2026-02-04 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218316-001 11382957 2031-12-16 Drug product 2026-01-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218316-001 10278923 2034-05-02 U-4389 2026-01-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218316-001 12239739 2034-05-02 U-4388 2026-01-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N218316-001 11833248 2039-02-01 U-4387 Drug product 2026-01-16 011fe1cb6892…
Observed Orange Book exclusivity history# openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 4 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Ozempic SEMAGLUTIDE A-S Medication Solutions 42bdd912-2393-44c4-b7e0-47672ca28991 2026-07-30 Boxed warning, Warnings, Adverse reactions Name fallback generic name: SEMAGLUTIDE WEGOVY SEMAGLUTIDE A-S Medication Solutions f5e548d0-cc79-4c34-a3f5-e20a5b8b6564 2024-04-23 Boxed warning, Warnings, Adverse reactions Name fallback brand name: WEGOVY generic name: SEMAGLUTIDE Ozempic SEMAGLUTIDE A-S Medication Solutions 979e4df4-0597-48ea-b51c-0f699fa6d166 2023-11-22 Boxed warning, Warnings, Adverse reactions Name fallback generic name: SEMAGLUTIDE OZEMPIC SEMAGLUTIDE A-S Medication Solutions e6da837c-0da0-41d6-973c-5559bf764367 2023-11-17 Boxed warning, Warnings, Adverse reactions Name fallback generic name: SEMAGLUTIDE
Documents# Document, Submission type, Date table Document Submission type Date 85893 SUPPL 2026-05-12 85516 SUPPL 2026-03-24 85500 SUPPL 2026-03-24 85453 SUPPL 2026-03-23 85194 SUPPL 2026-03-02 85179 SUPPL 2026-02-27 84941 SUPPL 2026-02-05 84886 SUPPL 2026-01-30 84543 ORIG 2025-12-23 84499 ORIG 2025-12-23